Technical Analysis for SPPI - Spectrum Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 9.32 -1.27% -0.12
SPPI closed down 1.27 percent on Wednesday, September 18, 2019, on 1.15 times normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical SPPI trend table...

Date Alert Name Type % Chg
Fell Below 200 DMA Bearish 0.00%
Slingshot Bullish Bullish Swing Setup 0.00%
Upper Bollinger Band Walk Strength 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
200 DMA Support Bullish -1.27%
Upper Bollinger Band Walk Strength -1.27%
Wide Bands Range Expansion -1.27%
Overbought Stochastic Strength -1.27%
Upper Bollinger Band Touch Strength -1.27%

Older signals for SPPI ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Spectrum Pharmaceuticals, Inc., a biotechnology company, engages in acquiring, developing, and commercializing prescription drug products primarily in the areas of hematology and oncology. The company's oncology products include FUSILEV for patients with osteosarcoma after high-dose methotrexate therapy, and to diminish toxicity and counteract the effects of impaired methotrexate elimination or inadvertent overdose of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma; and ZEVALIN, a prescribed form of cancer therapy which combines a source of radiation with an antibody. It also develops apaziquone that is under Phase III clinical trial for non-muscle invasive bladder cancer; and belinostat, which is under Phase II registrational trial for the various hematological and solid tumors. In addition, the company develops ozarelix that is under randomized phase II clinical trial in prostate cancer patients; ortataxel, which has completed Phase II studies in solid tumor patients; lucanthone, an orally administered small-molecule that has completed preclinical tests; SPI-1620, which has completed Phase I study is a peptide agonist of endothelin B receptors; RenaZorb, a second-generation lanthanum-based nanoparticle phosphate binding agent; and SPI-2012, a drug for the treatment of chemotherapy induced neutropenia. It has strategic collaborations with Allergan, Inc., Nippon Kayaku Co. Ltd., and Handok Pharmaceuticals Co. Ltd. for the development and commercialization of apaziquone; and TopoTarget A/S for the development and commercialization of belinostat. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is based in Henderson, Nevada.
Medicine Biotechnology Health Cancer Chemotherapy Radiation Prostate Cancer Solid Tumor Cancer Therapy Osteosarcoma Treating Cancer Non Muscle Invasive Bladder Cancer Oncology Products Neutropenia Ozarelix
Is SPPI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 21.8
52 Week Low 6.22
Average Volume 699,322
200-Day Moving Average 9.4094
50-Day Moving Average 7.9054
20-Day Moving Average 8.169
10-Day Moving Average 8.732
Average True Range 0.5496
ADX 24.95
+DI 32.1389
-DI 16.1923
Chandelier Exit (Long, 3 ATRs ) 8.3312
Chandelier Exit (Short, 3 ATRs ) 8.5488
Upper Bollinger Band 9.8571
Lower Bollinger Band 6.4809
Percent B (%b) 0.84
BandWidth 41.329416
MACD Line 0.429
MACD Signal Line 0.2332
MACD Histogram 0.1958
Fundamentals Value
Market Cap 734.27 Million
Num Shares 78.8 Million
EPS -1.00
Price-to-Earnings (P/E) Ratio -9.32
Price-to-Sales 11.56
Price-to-Book 7.68
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.45
Resistance 3 (R3) 10.47 10.11 10.26
Resistance 2 (R2) 10.11 9.83 10.10 10.19
Resistance 1 (R1) 9.72 9.65 9.54 9.70 10.13
Pivot Point 9.36 9.36 9.28 9.35 9.36
Support 1 (S1) 8.97 9.08 8.79 8.95 8.51
Support 2 (S2) 8.61 8.90 8.60 8.45
Support 3 (S3) 8.22 8.61 8.38
Support 4 (S4) 8.20